hrp0092fc6.2 | Bone, Growth Plate and Mineral Metabolism Session 2 | ESPE2019

Zone Wise Cell Separation Methods Comparison, Based on Relative Expression of Specific Growth Plate Markers in a Pig Model

Javanmardi Alireza , Raimann Adalbert , Egerbacher Monika , Sagmeister Susane , Gleiss Andreas , Haeusler Gabriele

Introduction: Longitudinal skeletal growth is achieved by enchondral ossification in epiphyseal growth plates (GP) of long bones and vertebrae. These highly organized cartilaginous tissues contain chondrocytes of all differentiational stages classified in three distinct zones named resting, proliferative and hypertrophic. Separated analysis of individual zones is essential in basic GP research thus efficiency of different zonal separation methods confers high ...

hrp0092p1-76 | GH and IGFs | ESPE2019

The Diagnostic Value of Serum Acid-labile Subunit (ALS) Alone and in Combination with IGF-1 and IGFBP-3 in the Diagnosis of Idiopathic Growth Hormone Deficiency (iGHD)

Chen Jiajia , Ertl Diana- Alexandra , Andreas Gleiss , Janu Dominik , Sagmeister Susanne , Raimann Adalbe , Gong ChunXiu , Haeusler Gabriele

Background: The acid-labile subunit (ALS) is the crucial third player in the tertiary complex for its function of prolonging the half-life of the IGF1-IGFBP3 binary complexes. IGF1 and IGFBP3 are routinely determined during the diagnostic work-up for growth hormone deficiency (GHD). The aim of the study is to evaluate the relevance of serum ALS as an additional biomarker, alone or in combination with IGF1 and IGFBP3, in the diagnosis of GHD.<p class="abste...

hrp0095fc2.6 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Pseudohypoparathyroidism Type 1A (PHP1A): Growth patterns under growth hormone therapy for short stature

Ertl Diana-Alexandra , Mantovani Giovanna , Perez de Nanclares Guiomar , Gleiss Andreas , Hanna Patrick , Marta Elli Francesca , Pereda Arrate , Rothenbuhler Anya , Audrain Christelle , Berkenou Jugurtha , Linglart Agnes

Background: Pseudohypoparathyroidism 1A, newly classified as inactivating PTH/PTHrP signaling disorder type 2 (iPPSD2), is defined by resistance to parathyroid hormone, short stature and early-onset obesity. Short stature is caused by skeletal dysplasia and additionally, in some cases, also by the coexistence of growth hormone deficiency, as other hormonal resistances might be present (e.g. thyroid-stimulating hormone, growth hormone releasing hormone (GHRH), ...

hrp0097p1-121 | Growth and Syndromes | ESPE2023

First year reponse to growth hormone (GH) therapy is related to long term outcome in GH deficiency (GHD) but not in children born small for gestational age (SGA)

Hartmann Gabriele , Ertl Diana-Alexandra , Raimann Adalbert , Haufler Florentina , Gleiss Andreas , Ashraf Soliman , Mai Alqubasi , Tawa Olukade , Hamdy Ali , Mohamed Alturk , Nada Alaaraj , Noor Hamed , Shayma Ahmed

In the history of biosynthetic GH, first prediction models on long term outcome of therapy were based on large multinational cohorts of various growth disorders and have concentrated on GH dose. In this study we analyzed the 1st year and final height (FH) data in a large single center cohort (center of expertise for rare growth disorders) and compared patient outcome and predictions in GHD and SGA. Our aim was to predict treatment outcome using simple previously suggested para...